JP3119483B2 - 喘息の処置における細胞間付着分子とその結合性リガンド - Google Patents

喘息の処置における細胞間付着分子とその結合性リガンド

Info

Publication number
JP3119483B2
JP3119483B2 JP02505457A JP50545790A JP3119483B2 JP 3119483 B2 JP3119483 B2 JP 3119483B2 JP 02505457 A JP02505457 A JP 02505457A JP 50545790 A JP50545790 A JP 50545790A JP 3119483 B2 JP3119483 B2 JP 3119483B2
Authority
JP
Japan
Prior art keywords
icam
family
vol
asthma
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP02505457A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04504127A (ja
Inventor
ウェグナー、クレイグ・ディー
ガンデル、ロバート・エイチ
ロスレイン、ロバート
Original Assignee
ベーリンガー・インゲルハイム・ファーマシュウティカルズ、インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー・インゲルハイム・ファーマシュウティカルズ、インコーポレイティッド filed Critical ベーリンガー・インゲルハイム・ファーマシュウティカルズ、インコーポレイティッド
Publication of JPH04504127A publication Critical patent/JPH04504127A/ja
Application granted granted Critical
Publication of JP3119483B2 publication Critical patent/JP3119483B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP02505457A 1989-03-09 1990-03-09 喘息の処置における細胞間付着分子とその結合性リガンド Expired - Lifetime JP3119483B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US32123789A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32101889A 1989-03-09 1989-03-09
US321,239 1989-03-09
US321,237 1989-03-09
US321,018 1989-03-09
US32448189A 1989-03-16 1989-03-16
US324,481 1989-03-16
US40140989A 1989-09-01 1989-09-01
US401,409 1989-09-01

Publications (2)

Publication Number Publication Date
JPH04504127A JPH04504127A (ja) 1992-07-23
JP3119483B2 true JP3119483B2 (ja) 2000-12-18

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP02505457A Expired - Lifetime JP3119483B2 (ja) 1989-03-09 1990-03-09 喘息の処置における細胞間付着分子とその結合性リガンド

Country Status (13)

Country Link
EP (1) EP0387701B1 (enExample)
JP (1) JP3119483B2 (enExample)
KR (1) KR0177519B1 (enExample)
AT (1) ATE79270T1 (enExample)
AU (1) AU638450B2 (enExample)
CA (1) CA2047721C (enExample)
DE (1) DE69000248T2 (enExample)
DK (1) DK0387701T3 (enExample)
ES (1) ES2035668T3 (enExample)
GR (1) GR3006073T3 (enExample)
HU (1) HU216313B (enExample)
NZ (1) NZ232868A (enExample)
WO (1) WO1990010453A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (en) * 1990-07-20 1999-09-01 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
AU8765391A (en) * 1990-10-03 1992-04-28 Boehringer Ingelheim Pharmaceuticals, Inc. Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
ES2094837T3 (es) * 1991-04-03 1997-02-01 Boehringer Ingelheim Pharma Metodo para inhibir la toxicidad pulmonar por oxigeno.
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
JPH06502195A (ja) * 1991-07-31 1994-03-10 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 内皮性白血球粘着分子−１およびそれに対する抗体の喘息治療における使用
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
RU94046450A (ru) * 1992-06-22 1996-10-10 Майлз Инк. (US) Мультимерная icam-i, способ усиления связывания icam-i с лигандом, фармацевтическая композиция, способ индукции декансидации, способ необратимого ингибирования заражения клеток
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ｂａｓｉｃ ａｎｄ Ｃｌｉｎｉｃａｌ Ｉｍｍｕｎｏｌｏｇｙ，（１９８０）ｐ．５１８−５２１
Ｃｅｌｌ，Ｖｏｌ．５１，（１９８７）ｐ．８１３−８１９
Ｆｕｎｄａｍｅｎｔａｌ Ｉｍｍｕｎｏｌｏｇｙ，（１９８４）ｐ．７０７−７１６
Ｊ．Ｉｍｍｕｎｏｌ．，Ｖｏｌ．１３７，Ｎｏ．１，（１９８６）ｐ．２４５−２５４
Ｊ．Ｉｍｍｕｎｏｌ．，Ｖｏｌ．１３７，Ｎｏ．４，（１９８６）ｐ．１２７０−１２７４

Also Published As

Publication number Publication date
WO1990010453A1 (en) 1990-09-20
EP0387701A1 (en) 1990-09-19
DK0387701T3 (da) 1992-12-07
HU216313B (hu) 1999-06-28
ES2035668T3 (es) 1993-04-16
KR920700667A (ko) 1992-08-10
NZ232868A (en) 1995-05-26
ATE79270T1 (de) 1992-08-15
HU902883D0 (en) 1991-12-30
CA2047721C (en) 2004-01-06
CA2047721A1 (en) 1990-09-10
AU638450B2 (en) 1993-07-01
AU5349990A (en) 1990-10-09
EP0387701B1 (en) 1992-08-12
DE69000248D1 (de) 1992-09-17
JPH04504127A (ja) 1992-07-23
GR3006073T3 (enExample) 1993-06-21
DE69000248T2 (de) 1993-01-07
KR0177519B1 (ko) 1999-03-20
HUT65843A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
JP3119483B2 (ja) 喘息の処置における細胞間付着分子とその結合性リガンド
US5324510A (en) Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
JP3288042B2 (ja) 細胞間接着分子−３およびその結合リガンド
US7666432B2 (en) Methods of suppressing fibrosis and fibrocyte formation
US6358510B1 (en) ICAM-1 derivatives with altered ability to bind LFA-1
US8187608B2 (en) Treatment of Fibrosis related disorders
US5288854A (en) Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
JPH08507860A (ja) リンパ球走化性誘引物質に基づくアッセイおよび治療方法
CN102257001A (zh) 治疗自体免疫和炎性病症的可溶性多肽
WO1993013798A1 (en) Treatment for asthma
US5831036A (en) Soluble fragments of human intercellular adhesion molecule-1
JP3502229B2 (ja) アレルゲン遺伝子を含む組換え真核細胞プラスミドおよびアレルギー性疾患の予防および／または治療のためのその使用
WO1993006842A1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
EP0972032B1 (en) Peptides for the treatment of systemic lupus erythematosus
Guo et al. Eotaxin expression in Sephadex-induced lung injury in rats
WO1995027736A1 (en) Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
US6797270B1 (en) Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
EP1025223A2 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JPH06502195A (ja) 内皮性白血球粘着分子−１およびそれに対する抗体の喘息治療における使用
AU665232C (en) Treatment for asthma
DD297417A5 (de) Interzellulares adhaesionsmolekuel-2 und seine bindungsliganden
JPH06145199A (ja) Ｉｃａｍ−１のｍａｃ−１結合部位

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071013

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081013

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081013

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091013

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091013

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101013

Year of fee payment: 10

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101013

Year of fee payment: 10